Anti mouse cd45.2 pe

Manufactured by Thermo Fisher Scientific

Anti-mouse CD45.2-PE is a fluorescently labeled antibody used to detect and identify mouse CD45.2-positive cells in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Pe anti human cd86, by BioLegend (1 mentions) Retinoic acid, by Merck Group (1 mentions) Anti mouse cd45.1 apc, by Thermo Fisher Scientific (1 mentions) Anti human cd14 apc, by Thermo Fisher Scientific (1 mentions) Anti mouse cd117 c kit fitc, by Thermo Fisher Scientific (1 mentions) Anti human cd34 fitc, by Thermo Fisher Scientific (1 mentions) Annexin 5 apoptosis detection kit, by Thermo Fisher Scientific (1 mentions) Fortessa cell analyzer, by BD (1 mentions)

Spelling variants of this product

Anti-CD45 (119 citations) CD45-PE (59 citations) Anti-CD45-PE (24 citations) Anti-mouse CD45 (14 citations) CD45.2-PE (10 citations) PE anti-mouse CD45 (5 citations)

2 protocols using anti mouse cd45.2 pe

Myeloid Differentiation Analysis via Flow Cytometry

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry analysis with surface markers was conducted as described previously with some modifications (Su et al., 2018 (link)). Retinoic acid (R2625, Sigma-Aldrich) was utilized to induced myeloid differentiation in NB4 cells. Antibodies used included anti-mouse CD45.1 APC (17-0453-82, eBioscience), anti-mouse CD45.2-PE (12-0454-83, Thermo Fisher Scientific), anti-mouse CD117 (c-Kit) FITC (17-1171-82, eBioscience), anti-Human CD33 PE (12-0339-42, Thermo Fisher Scientific), anti-Human CD45 BV786 (563716, BD Horizon), PE anti-mouse/human CD11b antibody (12-0118-42, eBioscience), anti-Human CD15 APC (17-0158-42, eBioscience), anti-Human CD14 APC (17-0149-42, eBioscience), anti-Human LILRB4 PE (333008, BioLegend), anti-Human LILRB4 APC (17-5139-42, eBioscience), anti-human CD209 FITC (330103, BioLegend), anti-human CD86 PE (374205, BioLegend), anti-Mouse Lilrb4 Alexa Fluor 647 (144906, BioLegend), and anti-Human CD34 FITC (11-0349-42, eBioscience).

Su R., Dong L., Li Y., Gao M., Han L., Wunderlich M., Deng X., Li H., Huang Y., Gao L., Li C., Zhao Z., Robinson S., Tan B., Qing Y., Qin X., Prince E., Xie J., Qin H., Li W., Shen C., Sun J., Kulkarni P., Weng H., Huang H., Chen Z., Zhang B., Wu X., Olsen M.J., Müschen M., Marcucci G., Salgia R., Li L., Fathi A.T., Li Z., Mulloy J.C., Wei M., Horne D, & Chen J. (2020). Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer cell, 38(1), 79-96.e11.

+ Open protocol

+ Expand

Characterizing Leukemic Cells by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry was performed in the City of Hope core facility and data was analyzed with FlowJo. Briefly, for c-kit expression, cells were stained with anti-mouse CD45.2-PE (12-0454-83, Thermo Fisher Scientific) and anti-mouse c-kit-APC (17-1171-83, eBioscience) and analyzed on BD Fortessa Cell Analyzer following the manufacturer's directions. For data analysis, we gated for live, singlets, with positive CD45.2 expression to selectively focus on leukemic cells before analyzing for c-Kit expression. For apoptosis analysis, cells were stained with 7-AAD and Annexin V using the Annexin V Apoptosis Detection Kit (88-8007-74, eBioscience) and analyzed on BD Fortessa Cell Analyzer according to the manufacturer's instructions.

Zhang Z., Zhou K., Han L., Small A., Xue J., Huang H., Weng H., Su R., Tan B., Shen C., Li W., Zhao Z., Qing Y., Qin X., Wang K., Leung K., Boldin M., Chen C.W., Ann D., Qian Z., Deng X., Chen J, & Chen Z. (2023). RNA m6A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression. Genes & Diseases, 11(1), 382-396.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!